133 related articles for article (PubMed ID: 11982740)
1. Treatment of benign nodular goitre with mildly suppressive doses of L-thyroxine: effects on bone mineral density and on nodule size.
Baldini M; Gallazzi M; Orsatti A; Fossati S; Leonardi P; Cantalamessa L
J Intern Med; 2002 May; 251(5):407-14. PubMed ID: 11982740
[TBL] [Abstract][Full Text] [Related]
2. Effects on bone mineral density by treatment of benign nodular goiter with mildly suppressive doses of L-thyroxine in a cohort women study.
Appetecchia M
Horm Res; 2005; 64(6):293-8. PubMed ID: 16269872
[TBL] [Abstract][Full Text] [Related]
3. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
4. L-thyroxin treatment and post-menopausal osteoporosis: relevance of the risk profile present in clinical history.
La Vignera S; Vicari E; Tumino S; Ciotta L; Condorelli R; Vicari LO; Calogero AE
Minerva Ginecol; 2008 Dec; 60(6):475-84. PubMed ID: 18981975
[TBL] [Abstract][Full Text] [Related]
5. Levothyroxine suppressive therapy is partially effective in treating patients with benign, solid thyroid nodules and multinodular goiters.
Lima N; Knobel M; Cavaliere H; Sztejnsznajd C; Tomimori E; Medeiros-Neto G
Thyroid; 1997 Oct; 7(5):691-7. PubMed ID: 9349571
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of L-thyroxine (L-T4) therapy on the volume of the thyroid gland and nodules in patients with euthyroid nodular goiter (ENG)].
Diacinti D; Salabè GB; Olivieri A; D'Erasmo E; Tomei E; Lotz-Salabè H; De Martinis C
Minerva Med; 1992 Nov; 83(11):745-51. PubMed ID: 1461545
[TBL] [Abstract][Full Text] [Related]
7. The effect of suppressive thyroxine therapy in nodular goiter in postmenopausal women and 2 year's bone mineral density change.
Chen CY; Chen ST; Huang BY; Hwang JS; Lin JD; Liu FH
Endocr J; 2018 Nov; 65(11):1101-1109. PubMed ID: 30158361
[TBL] [Abstract][Full Text] [Related]
8. [Therapy with L-thyroxine in thyroid struma. Study with ultrasonic evaluation].
Peta M; Cartasegna S; Fabiani MP; Macchi R; Vecchi G; Costantino D
Recenti Prog Med; 1989 Jun; 80(6):320-5. PubMed ID: 2672195
[TBL] [Abstract][Full Text] [Related]
9. Prospective study of bone loss in pre- and post-menopausal women on L-thyroxine therapy for non-toxic goitre.
De Rosa G; Testa A; Giacomini D; Carrozza C; Astazi P; Caradonna P
Clin Endocrinol (Oxf); 1997 Nov; 47(5):529-35. PubMed ID: 9425392
[TBL] [Abstract][Full Text] [Related]
10. Spinal bone mass after long-term treatment with L-thyroxine in postmenopausal women with thyroid cancer and chronic lymphocytic thyroiditis.
Hawkins F; Rigopoulou D; Papapietro K; Lopez MB
Calcif Tissue Int; 1994 Jan; 54(1):16-9. PubMed ID: 8118747
[TBL] [Abstract][Full Text] [Related]
11. Iodized salt improves the effectiveness of L-thyroxine therapy after surgery for nontoxic goitre: a prospective and randomized study.
Carella C; Mazziotti G; Rotondi M; Del Buono A; Zito G; Sorvillo F; Manganella G; Santini L; Amato G
Clin Endocrinol (Oxf); 2002 Oct; 57(4):507-13. PubMed ID: 12354133
[TBL] [Abstract][Full Text] [Related]
12. Postintervention serum TSH levels may be useful to differentiate patients who should undergo levothyroxine suppressive therapy after thyroid surgery for multinodular goiter in a region with moderate iodine deficiency.
Rotondi M; Amato G; Del Buono A; Mazziotti G; Manganella G; Biondi B; Sinisi AM; Santini L; Bellastella A; Carella C
Thyroid; 2000 Dec; 10(12):1081-5. PubMed ID: 11201853
[TBL] [Abstract][Full Text] [Related]
13. Solitary nodular disease and multinodular goiter: a retrospective study on suppressive versus replacement levothyroxine therapy.
Paggi A; Persegani-Trimarchi C; Russo P; Mastropasqua M; Mosetti MA; Losi T; Leri O
Endocr Res; 1999 May; 25(2):229-38. PubMed ID: 10382684
[TBL] [Abstract][Full Text] [Related]
14. Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter.
Güllü S; Gürses MA; Başkal N; Uysal AR; Kamel AN; Erdoğan G
Endocr J; 1999 Feb; 46(1):221-6. PubMed ID: 10426591
[TBL] [Abstract][Full Text] [Related]
15. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27 914 patients.
Fiore E; Rago T; Provenzale MA; Scutari M; Ugolini C; Basolo F; Di Coscio G; Miccoli P; Grasso L; Pinchera A; Vitti P
Endocr Relat Cancer; 2010 Mar; 17(1):231-9. PubMed ID: 20167722
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density in patients with endogenous subclinical hyperthyroidism: is this thyroid status a risk factor for osteoporosis?
Földes J; Tarján G; Szathmari M; Varga F; Krasznai I; Horvath C
Clin Endocrinol (Oxf); 1993 Nov; 39(5):521-7. PubMed ID: 8252739
[TBL] [Abstract][Full Text] [Related]
17. Effect of TSH-suppressive doses of levothyroxine on bone mineral density in Thai women.
Ongphiphadhanakul B; Puavilai G; Rajatanavin R
J Med Assoc Thai; 1996 Sep; 79(9):563-7. PubMed ID: 8996984
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological correlation of serum TSH in patients with thyroid nodule.
Mondal HP; Sen S; Sasmal S; Ghosal PK; Mukhopadhyay SK; Mukhopadhyay M
J Indian Med Assoc; 2011 May; 109(5):330, 335, 338. PubMed ID: 22187768
[TBL] [Abstract][Full Text] [Related]
19. Bone changes in pre- and postmenopausal women with thyroid cancer on levothyroxine therapy: evolution of axial and appendicular bone mass.
Jódar E; Begoña López M; García L; Rigopoulou D; Martínez G; Hawkins F
Osteoporos Int; 1998; 8(4):311-6. PubMed ID: 10024900
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
Guo CY; Weetman AP; Eastell R
Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
